<DOC>
	<DOCNO>NCT01135225</DOCNO>
	<brief_summary>The purpose EVOLVE Trial ass safety performance everolimus-eluting Evolution stent treatment de novo atherosclerotic lesion 28 mm length native coronary artery 2.25 mm 3.5 mm diameter . The safety performance two different drug release rate formulation Evolution Stent compare commercially available PROMUS ( TM ) Element ( TM ) drug-eluting stent .</brief_summary>
	<brief_title>Non-inferiority Trial Assess Safety Performance Evolution Coronary Stent</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patient must least 18 year age Patient ( legal guardian ) understand trial requirement treatment procedure provide write informed consent trialspecific test procedure perform Patient eligible percutaneous coronary intervention ( PCI ) Patient symptomatic coronary artery disease document silent ischemia Patient acceptable candidate coronary artery bypass grafting ( CABG ) Patient leave ventricular ejection fraction ( LVEF ) ≥30 % measure within 60 day prior enrollment Patient willing comply protocolrequired followup evaluation Patient clinical symptom and/or electrocardiogram ( ECG ) change consistent acute MI Patient unstable angina recent MI ( within 72 hour ) must CK/CKMB troponin document prior procedure exclude follow criterion meet time index procedure : 1 . If CK MB &gt; 2× upper limit normal ( ULN ) , patient exclude regardless CK Total . 2 . If CK Total &gt; 2× ULN , either CKMB troponin must draw patient exclude either CKMB troponin abnormal . 3 . If neither CK Total CK MB drawn troponin , patient exclude : Troponin &gt; 1× ULN patient least one following : Patient ischemic symptom ECG change indicative ongoing ischemia ( e.g. , &gt; 1 mm ST segment elevation depression consecutive lead new left bundle branch block [ LBBB ] ) Development pathological Q wave ECG ; ; Imaging evidence new loss viable myocardium new regional wall motion abnormality Note : Patients stable angina must CK/CKMB troponin drawn prior index procedure . However , result patient need available prior index procedure exclusion criterion base study . Patient receive organ transplant wait list organ transplant Patient receiving schedule receive chemotherapy within 30 day index procedure Patient receive oral intravenous immunosuppressive therapy ( e.g. , inhaled steroid exclude ) know lifelimiting immunosuppressive autoimmune disease ( e.g. , human immunodeficiency virus , systemic lupus erythematosus , include diabetes mellitus ) Patient receive chronic ( ≥72 hour ) anticoagulation therapy ( e.g. , heparin , coumadin ) indication acute coronary syndrome Patient platelet count &lt; 100,000 cells/mm3 &gt; 700,000 cells/mm3 Patient white blood cell ( WBC ) count &lt; 3,000 cells/mm3 Patient document suspect liver disease , include laboratory evidence hepatitis Patient dialysis know renal insufficiency ( e.g . serum creatinine level &gt; 2.0 mg/dL ) Patient active peptic ulcer disease , active gastrointestinal ( GI ) bleed , bleed diathesis coagulopathy , refuse transfusion Patient cerebrovascular accident ( CVA ) transient ischemic attack ( TIA ) within past 6 month , permanent neurologic defect may cause noncompliance protocol Target vessel ( include side branch ) treat type PCI ( e.g. , balloon angioplasty , stent , cut balloon , atherectomy ) within 12 month prior index procedure Target vessel treat within 10 mm proximal distal target lesion ( visual estimate ) type PCI ( e.g. , balloon angioplasty , stent , cut balloon , atherectomy ) time prior index procedure Nontarget vessel ( include side branch ) treat type PCI ( e.g. , balloon angioplasty , stent , cut balloon , atherectomy ) within 24 hour prior index procedure Note : 1 lesion nontarget vessel may treat index procedure prior treatment target ( study ) lesion . The treatment lesion ( ) nontarget vessel 24 hour prior procedure preclude treatment additional nontarget lesion index procedure . For example , patient could RCA lesion treat 7 day prior index procedure nontarget lesion LCx target lesion LAD treat index procedure . Planned actual target vessel treatment unapproved device , directional rotational coronary atherectomy , laser , cut balloon , transluminal extraction catheter immediately prior stent placement Planned PCI CABG index procedure Patient previously treat time coronary intravascular brachytherapy Patient know allergy trial stent system protocolrequired concomitant medication ( e.g. , stainless steel , platinum , chromium , nickel , tungsten , acrylic , fluoropolymers , everolimus , thienopyridines , aspirin , contrast ) adequately premedicated Patient one following . Other serious medical illness ( e.g. , cancer , congestive heart failure ) may reduce life expectancy le 24 month Current problem substance abuse ( e.g. , alcohol , cocaine , heroin , etc . Planned procedure may cause noncompliance protocol confound data interpretation Patient participate another investigational drug device clinical trial reach primary endpoint Patient intend participate another investigational drug device clinical trial within 12 month index procedure Patient know intention procreate within 12 month index procedure . ( Women childbearing potential sexually active must agree use reliable method contraception time screen 12 month index procedure . ) Patient woman pregnant nursing . ( A pregnancy test must perform within 7 day prior index procedure woman childbearing potential . ) Patient 1 target lesion 1 nontarget lesion treat index procedure Angiographic Inclusion criterion ( Visual Estimate ) : Target lesion must de novo lesion locate native coronary artery visually estimate reference vessel diameter ( RVD ) ≥ 2.25 mm ≤3.5 mm . Target lesion length must ≤ 28 mm ( visual estimate ) Target lesion must visually estimate stenosis ≥50 % &lt; 100 % Thrombolysis Myocardial Infarction ( TIMI ) flow &gt; 1 . Target lesion must successfully predilatated . Angiographic Exclusion criterion ( visual estimate ) : Target lesion meet follow criterion . Left main location Located within 5 mm origin leave anterior descending ( LAD ) , leave circumflex ( LCX ) RCA visual estimate Located within saphenous vein graft arterial graft Will access via saphenous vein graft arterial graft Involves side branch ≥2.0 mm diameter visual estimate Involves side branch &lt; 2.0 mm diameter visual estimate require treatment TIMI flow 0 ( total occlusion ) TIMI flow 1 prior guide wire cross Excessive tortuosity proximal within lesion Excessive angulation proximal within lesion Target lesion and/or target vessel proximal target lesion moderately severely calcified visual estimate Restenotic previous intervention Thrombus , possible thrombus , present target vessel Target lesion cover single study stent Patient unprotected leave main coronary artery disease ( &gt; 50 % diameter stenosis ) Patient protect leave main coronary artery disease target lesion LAD LCX Patient additional clinically significant lesion ( ) target vessel intervention within 12 month index procedure may require Nontarget lesion treat index procedure meet follow criterion . Located within target vessel Located within bypass graft ( venous arterial ) Left main location Chronic total occlusion Involves complex bifurcation ( e.g. , bifurcation lesion require treatment 1 stent ) Requires additional unplanned stent Treatment deem clinical angiographic success Treatment complete prior treatment target lesion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Drug-eluting stent</keyword>
	<keyword>Percutaneous coronary intervention</keyword>
	<keyword>Stent implantation</keyword>
	<keyword>Evolution Stent System</keyword>
	<keyword>Biodegradable polymer coating</keyword>
	<keyword>Feasibility study</keyword>
</DOC>